- Tumors969
- Cancer575
- Pathologic Processes568
- Pathology564
- Immune System Diseases437
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors969
- Cancer575
- Pathologic Processes568
- Pathology564
- Immune System Diseases437
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PD-L1 negative
- EGFR negative
- PR positive
- ALK negative
- EGFR positive
- ER negative
- PR negative
- CD20 positive
- KRAS positive
- BRAF positive
- BRAF negative
- ROS1 negative
- ALK positive
- BRCA1 positive
- p16 positive
- BRCA2 positive
- MYC positive
- PIK3CA positive
- p16 negative
- HLA positive
- HLA-A positive
- HR positive
- MET positive
- Ex19del positive
- L858R positive
- RET positive
- TP53 positive
- BCL2 positive
- HBsAg positive
- IDH positive
- ROS1 positive
- BCL6 positive
- BCR-ABL1 positive
- CD19 positive
- CD5 positive
- HLA-A negative
- HPV negative
- MET negative
- RET negative
- TTR positive
- anti-dsDNA positive
- ANA positive
- BRCA positive
- BRCA1 negative
- CCND1 positive
- FGFR2 positive
- HLA negative
- HPV positive
- IDH negative
- NTRK negative
- PALB2 positive
- RB1 negative
- RB1 positive
- T790M positive
- TP53 negative
- TROP2 negative
- TROP2 positive
- ctDNA positive
- dMMR positive
- APP positive
- BRCA2 negative
- C5 positive
- CD23 positive
- CFTR positive
- CLDN18.2 positive
- COL7A1 positive
- EBV positive
- FMR1 positive
- MDM2 positive
- MMR positive
- PSEN1 positive
- PSEN2 positive
- PTEN positive
- Philadelphia chromosome positive
- RF positive
- SPINK5 positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- ABCA4 positive
- ALPL positive
- ATM positive
- Aβ1-42 positive
- CD20 negative
- COL1A1 positive
- COL1A2 positive
- DMD positive
- ER/PR positive
- FLT3 negative
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GLA positive
- HBB positive
- HRD positive
- HbE positive
- HbSS positive
- IGHV negative
- IGHV positive
- JAK2 positive
- KIT positive
- KRAS negative
- L861Q positive
- MGMT negative
- MSI-H negative
- MSI-H positive
- MSS positive
- MYC negative
- NRAS negative
- NRAS positive
- NTRK positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PTEN negative
- Philadelphia chromosome negative
- PiZZ positive
- RAS negative
- RAS positive
- S768I positive
- SMN1 positive
- TTR negative
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- dMMR negative
- del(17p) negative
- kappa light chain positive
- lambda light chain positive
- other sickle cell syndrome variants positive
- p53 positive
- 11q del negative
- 11q del positive
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p del positive
- 17p negative
- 17p positive
- 17p13 deletion negative
- 19q negative
- 19q positive
- 1p negative
- 1p positive
- 1p/19q co-deletion positive
- 1p/19q loss positive
- 1p36 deletion positive
- 46 XX karyotype positive
- 5q SMA positive
- AAVrh74 antibody titers negative
- ABL-class fusion positive
- ABL-class fusions positive
- ACVR1 positive
- AChR positive
- AChR-Ab positive
- ADAMTS-13 negative
- ADAMTS-13 positive
- AFP positive
- AGXT positive
- AKT negative
- AKT positive
- ALAS2 positive
- ALT positive
- APOL1 positive
- AQP4 positive
- Acetylcholine receptor antibody positive
- Anti-CCP-2 positive
- Anti-HBc IgM negative
- Anti-Ro/SS-A positive
- Anti-SSA (Ro) positive
- Anti-SSB (La) positive
- Anti-Smith antibodies positive
- Anti-cyclic citrullinated peptide autoantibodies positive
- Antinuclear antibody positive
- Aβ1-40 positive
- Aβ1-42/Aβ1-40 ratio positive
- BCL2 translocation positive
- BCL6 translocation positive
- BCR-ABL1 e13a2 positive
- BCR-ABL1 e14a2 positive
- BCR-ABL1 fusion positive
- BRCA negative
- BTK-C481 positive
- C1-INH functional activity positive
- C1-INH positive
- C4 antigen level positive
- C5 SNP negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
2920 trials
Trials Without a Placebo
1
2
3
…50